A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas
Phase 2
Completed
NCT04917861
| Condition | Zika Virus |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | ModernaTX, Inc. |
|---|
| Status | Completed |
|---|
| Enrollment | 808 participants |
|---|
| Interventions | mRNA-1893 |
|---|
| Start date | Jun 7, 2021 |
|---|
| Completion date | Jul 26, 2024 |
|---|
| Results posted | Sep 25, 2025 |
|---|
Summary
This clinical study will evaluate the safety, tolerability, and reactogenicity of 2 dose levels of messenger RNA (mRNA)-1893 Zika vaccine in comparison to a placebo control in healthy participants who are flavivirus-seronegative and in participants who are flavivirus-seropositive.
Number of Participants With Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)
Up to 7 days post-vaccination · Participants
| Placebo | 86 Participants |
|---|
| mRNA-1893 Low Dose (2-Dose Regimen) | 164 Participants |
|---|
| mRNA-1893 High Dose (2-Dose Regimen) | 183 Participants |
|---|
| mRNA-1893 High Dose (1-Dose Regimen) | 163 Participants |
|---|
Number of Participants With Unsolicited Adverse Events (AEs)
Up to 28 days post-vaccination · Participants
| Placebo | 39 Participants |
|---|
| mRNA-1893 Low Dose (2-Dose Regimen) | 47 Participants |
|---|
| mRNA-1893 High Dose (2-Dose Regimen) | 52 Participants |
|---|
| mRNA-1893 High Dose (1-Dose Regimen) | 45 Participants |
|---|
Number of Participants With Serious Adverse Events (SAEs), AEs of Special Interest (AESIs)
Day 1 through Day 196 for Main Study and Day 197 through Day 700 for Extension Period · Participants
| Main Study: Placebo | 5 Participants |
|---|
| Main Study: mRNA-1893 Low Dose (2-Dose Regimen) | 2 Participants |
|---|
| Main Study: mRNA-1893 High Dose (2-Dose Regimen) | 4 Participants |
|---|
| Main Study: mRNA-1893 High Dose (1-Dose Regimen) | 7 Participants |
|---|
| Extension Period: Placebo | 5 Participants |
|---|
| Extension Period: mRNA-1893 Low Dose (2-Dose Regimen) | 4 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.